Clinical efficacy of gefitinib combined with pemetrexed and cisplatin targeted therapy in patients with EGFR mutation-positive non-small cell lung cancer
Yuwen Li-xia
Shi Hui-hui
Wu Tie-jun
Wang Rui-ling
Zheng Hai-feng
Abstract：Objective To investigate the clinical efficacy of gefitinib combined with pemetrexed and cisplatin in the treatment of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Methods A total of 325 patients with EGFR mutation-positive NSCLC admitted to Xingtai Central Hospital from January 2021 to January 2023 were selected as the research subjects. According to different treatment methods,they were divided into the chemotherapy group (n=139) and targeted therapy group (n=186). The patients in the chemotherapy group were treated with pemetrexed and cisplatin while those in the targeted therapy group were given gefitinib targeted therapy combined with pemetrexed and cisplatin. The clinical efficacy and tumor markers before treatment and after 4 cycles of treatment were compared between the two groups. The incidence of adverse reactions during treatment were counted in both groups. Results After 4 cycles of treatment,the disease control rate of 89.25％ (166/186) in targeted therapy group was higher than that of 77.70％ (108/139) in the chemotherapy group (x2=8.020,P=0.004). The levels of cancer antigen 125 (CA125),carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) in the targeted thera-py group and chemotherapy group ((84.09±16.53) U·mL-1,(38.84±11.47) ng·mL-1,(21.19±4.75) ng·mL-1,(97.88±24.59) U·mL-1,(49.08±15.61) ng·mL-1,(25.85±5.12) ng·mL-1) were decreased as compared with those before treatment ((268.57±36.32) U·mL-1,(126.05±23.77) ng·mL-1,(29.70±5.48) ng·mL-1,(275.06±43.11) U·mL-1,(121.48±31.01) ng·mL-1,(30.21±6.06) ng·mL-1),and they were lower in the targeted therapy group (P<0.05). The incidence of adverse reactions in the targeted therapy group was significantly lower than that in the chemotherapy group (P<0.05). Conclusion Gefitinib targeted therapy combined with pemetrexed and cis-platin has significant clinical efficacy in the treatment of EGFR mutation-positive NSCLC patients since it can reduce the levels of tumor markers and enhance the safety of chemotherapy. Therefore,it has good value of clinical application.
Keywords：GefitinibTargeted therapyPemetrexedCisplatinEpidermal growth factor receptorNon-small cell lung cancer
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 783-786 )